Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology

Area of Science:

• Biotechnology
• Nanomedicine
• Nucleic Acid Therapeutics

Background:

• Nucleic acid (NA) therapies are hindered by rapid degradation, poor cellular uptake, and inefficient endosomal escape.
• Effective delivery to the cell nucleus or cytosol is crucial for NA therapeutic efficacy.
• Existing challenges limit the clinical translation of NA-based treatments.

Purpose of the Study:

• To review the characteristics of various NA modalities.
• To illustrate how advanced nanoscale biotechnology aids NA therapy.
• To summarize and discuss nanocarrier features and challenges in NA delivery.

Main Methods:

• Review of current literature on NA therapy and nanocarrier systems.
• Analysis of advanced nanoscale biotechnology strategies for NA delivery.
• Discussion of clinical and preclinical studies involving nanocarriers for NA therapeutics.

Main Results:

• Nanoscale biotechnology offers strategies to control nanocarrier properties like size, charge, and responsiveness.
• These advanced delivery systems show promise for improving in vivo and in vitro NA delivery.
• Various nanocarriers have demonstrated potential in preclinical and clinical NA therapeutic studies.

Conclusions:

• Advanced nanoscale biotechnology is pivotal in overcoming major barriers in NA therapy development.
• Optimized nanocarriers can enhance the stability, targeting, and intracellular delivery of NA therapeutics.
• Future advancements in nanobiotechnology are expected to accelerate the clinical success of nucleic acid-based medicines.